Clinical Trial Update: Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing SHC014748M for relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• SHC014748M

Snippet

Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. | Conditions: Follicular Lymphoma(FL), Marginal Zone Lymphoma(MZL) | Phase 2 | Status: UNKNOWN